Highlights
– At a median follow-up of 64.1 months, pola‑R‑CHP produced a statistically significant 5‑year PFS benefit versus R‑CHOP (HR 0.77), with 5‑year PFS rates 64.9% vs 59.1%.
– Overall survival differences remain non‑significant at five years (HR 0.85); lymphoma‑related deaths were fewer with pola‑R‑CHP (46 vs 62).
– Patient‑reported outcomes showed rapid, sustained HRQoL improvements in both arms but highlighted higher symptom reporting by patients than clinicians.
– In older patients (particularly ≥70 years), exploratory analyses suggested clinically meaningful PFS gains with pola‑R‑CHP; safety was similar though febrile neutropenia rates were higher and G‑CSF prophylaxis is important.
